Recursion
SF 8.1AI biotech with cellular imaging and automation
AI biotech with cellular imaging and automation
DeepMind spinout for AI drug design
Quick decision guide
Not enough differentiated product data yet to make a strong automatic pick.
Overview
Recursion is an AI drug discovery company for pharma collaborators and internal programs, combining cellular imaging, automation, and machine learning to identify potential drug candidates.
Its fit depends on whether Recursion’s data-rich discovery model, partnership structure, and development timelines align with the buyer’s overall program goals.
Isomorphic Labs is a DeepMind spinout developing AI models for drug discovery, including protein structure prediction and molecule generation for pharmaceutical and biologics partners.
For suitably resourced partners, the central question is whether its collaborative model matches the program's scientific, operational, and commercial requirements.
Side-by-side
OVERLAP
Both tools cover similar catalog signals. The deciding factor is usually workflow fit, implementation needs, and ecosystem fit.
Shared capabilities
Shared workflows
Feature check
Use cases
The trade-offs
Final verdict
Current catalog data shows meaningful overlap between Recursion and Isomorphic Labs. Use the signals below to decide based on workflow, ecosystem, pricing, and implementation fit.
Recursion and Isomorphic Labs share 9 catalog signals, so the decision should focus on fit rather than broad capability alone.
Recursion has 3 visible decision signals and Isomorphic Labs has 3.
Isomorphic Labs has the higher SoftFinders Score in the current catalog data.